

A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia

SAGE Open Medicine
Volume 4: 1–10
© The Author(s) 2016
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050312116646030
smo.sagepub.com


David Rowell¹, Louisa G Gordon², Catherine M Olsen³
and David C Whiteman³

Abstract

Objectives: The composition of the medical costs incurred by people treated for basal cell and squamous cell carcinomas (hereafter keratinocyte cancers) is not adequately understood. We sought to compare the medical costs of individuals with or without keratinocyte cancers.

Methods: We used national health insurance data to analyze the direct medical costs of 2000 cases and 2000 controls nested within the QSkin prospective cohort study (n = 43,794) conducted in Australia. We reconstructed the medical history of patients using medical and pharmaceutical item codes and then compared the health service costs of individuals treated for keratinocyte cancers with those not treated for keratinocyte cancers.

Results: Individuals treated for keratinocyte cancers consumed on average AUD\$1320 per annum more in medical services than those without keratinocyte cancers. Only 23.2% of costs were attributed to the explicit treatment of keratinocyte cancers. The principal drivers of the residual costs were medical attendances, surgical procedures on the skin, and histopathology services. We found significant positive associations between history of treatment for keratinocyte cancers with treatments for other health conditions, including melanoma, cardiovascular disease, lipidemia, osteoporosis, rheumatoid arthritis, colorectal cancer, prostate cancer, and tuberculosis.

Conclusion: Individuals treated for keratinocyte cancers have substantially higher medical costs overall than individuals without keratinocyte cancers. The direct costs of skin cancer excision account for only one-fifth of this difference.

Keywords

Basal cell carcinoma, squamous cell carcinoma, keratinocyte cancer, costs of keratinocyte cancer comorbidities

Date received: 31 August 2015; accepted: 28 March 2016

Introduction

Keratinocyte cancer (KC) is the collective term for basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin.¹ Due to its high incidence, the aggregate costs of treating KC remains a concern in North America,^{2–5} Europe,^{6–9} Australia,¹⁰ New Zealand,¹¹ and Brazil.¹² KC is the most costly cancer to treat in Australia¹⁰ and the fifth most costly to treat in the United States.¹³ The increasing incidence of KC in North America,^{13,14} Europe,¹⁵ and Australia¹⁰ motivates the need for a thorough understanding of the medical costs of treating people with KC.

While several broad estimates of the cost of KC treatment have been published,^{3,5–10,12,16} few studies have used

¹The University of Queensland, Queensland Brain Institute, Asia-Pacific Centre for Neuromodulation, St Andrews War Memorial Hospital, Brisbane, QLD, Australia

²Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia

³QIMR Berghofer Medical Research Institute, Population Health Department, Royal Brisbane Hospital, Brisbane, QLD, Australia

Corresponding author:

David Rowell, The University of Queensland, Queensland Brain Institute, Asia-Pacific Centre for Neuromodulation, St Andrews War Memorial Hospital, Spring Hill, Brisbane, QLD 4000, Australia.
Email: d.rowell@uq.edu.au



individual-level data to explore direct personal costs in detail. Due to a high incidence and low mortality rate, KC data are seldom collected by national cancer registries.¹⁷ In the very few jurisdictions where data collection is mandated (e.g. Denmark), incomplete case registration¹⁸ can result in bias if registered patients are systematically different from the unregistered patients.¹⁹ Thus, obtaining accurate KC data is challenging, and there are limited data that adequately describe the costs of KC treatments.

Patients with KC can be affected by comorbid disease. The epidemiological literature remains inconclusive about incidence of correlated comorbidities, and the economic literature has not accurately determined the costs of treatment. KC is reported to be positively correlated with melanoma,^{20,21} other cancers,^{16,20–22} and several chronic diseases,^{18,23} and due its association with vitamin D,^{24–26} it is negatively correlated with second solid primary cancers²⁷ and prostate cancer.²⁵

To explore the burden of KC in detail, we used national health insurance data obtained through record-linkage to a very large prospective cohort study that was established specifically to study cancers of the skin. Here, we report an analysis in which we measured and categorized medical treatments utilized by a cohort of patients treated for KC.

Materials and methods

In 2011, the QSkin Sun and Health Study was initiated in Queensland, Australia, to investigate the role of environmental and genetic factors in the etiology of skin cancer.²⁸ An invitation and survey was sent to 193,344 persons selected at random from the Queensland Electoral Roll (voter registration is compulsory by law in Queensland, Australia, for all persons over the age of 18 years). Potential participants were aged 40–69 years and frequency matched by age and sex to the Queensland population, of whom 43,794 agreed to participate in the study.^{28,29} The respondents were asked to report demographic and socioeconomic characteristics as well as clinical data including skin phenotype, medical history, and exposure to sunlight.²⁸ In total 39,033 participants gave their consent for linkage to individual health service utilization data from 30 June 2011 to 30 June 2012 retained by the national health insurance scheme, Medicare Australia.

Medicare Australia is composed of two major funding instruments, the Medicare Benefits Scheme (MBS) and the Pharmaceutical Benefits Scheme (PBS). The MBS subsidizes fee-for-service medical care provided by Australia's medical practitioners as well as diagnostic, therapeutic, and imaging services. The MBS lists thousands of subsidized clinical services; each identified by a unique item code and assigned a scheduled subsidy. The PBS is a parallel funding instrument, which provides Australian residents affordable access to a wide range of medications listed on the PBS. The survey responses were linked to 12 months of health service

utilization data, denoted by MBS and PBS item numbers. Ethical approval for the study was received from the QIMR Berghofer Medical Research Institute Human Research Ethics Committee and the Department of Health and the Queensland University of Technology.

The treatment of KC will typically involve local excision or biopsy of the suspect skin lesion. Depending on the clinical staging at the time of presentation, other KC treatment costs can include attendance fees for general practitioners (GPs) and specialist practitioners, surgeries, anesthetic, skin grafting, inpatient care, and after care. In our data, a KC was identified if an individual had utilized any 1 of 41 MBS item codes, which explicitly described the excision of a BCC, SCC, or ablation of malignant neoplasm of skin (see Table 2). A sub-sample of 2000 randomly selected individuals with KC was matched 1:1 on gender and 5-year age categories to a group of controls.

The costs of medical and pharmaceutical services, as identified by MBS and PBS item codes, were summed for each individual. This estimate included the value of the MBS subsidy plus the individual co-payment. Where Medicare Australia fully reimburses the physician for their service, the co-payment will be zero. Costs are presented in 2012 AUD\$. Health service utilization, by cohort, is compared in league tables for frequency and cost.

The MBS and PBS item codes were also used to develop a clinical profile—albeit limited—for both cohorts. While in principle, there is no limit to the number of diseases, which one could consider, limited resources constrained the number of comorbidities, which were identified in the data. A literature review identified 17 comorbidities, which were reported to be correlated (positively or negatively) with KC. The selected comorbidities included three autoimmune diseases³⁰ (asthma, rheumatoid arthritis,³¹ and multiple sclerosis³²), two mental illnesses (depression³³ and anxiety³⁴), cardiovascular disease³⁵ and two associated risk factors (hypertension and hyperlipidemia), diabetes,³⁶ four cancers (melanoma,³⁷ breast,³⁸ prostate,³⁸ and colorectal³⁸), osteoporosis,^{39,40} Parkinson's disease,⁴¹ tuberculosis,⁴² and bronchitis.⁴⁰ The 17 selected comorbidities provide a good proxy for “health” insofar as they include 7 of the 10 most frequently managed chronic problems by Australia's GPs.⁴³

The *Merck manual*⁴⁴ was reviewed to compile a comprehensive list of diagnostic tests, medical and surgical procedures, and pharmaceuticals used to manage each comorbidity listed. Each therapeutic intervention was then matched to the corresponding item codes identified in a search of the MBS⁴⁵ and PBS⁴⁶ websites. A total of 1500 MBS and PBS item codes were used to identify the 17 comorbidities that are documented in the supplementary material provided by Rowell et al.⁴⁷ While not every treatment cited in the *Merck manual* could uniquely identify a diagnosis (e.g. analgesia), many treatments were able to identify a probable diagnosis (e.g. antihypertensive medication suggests hypertension).

Table 1. Demographic characteristics of people treated with or without KC in Queensland, 2010.

Characteristics	Cases (n = 2000)	Controls (n = 2000)	p-value
Female	984 (49.2)	1000 (50)	0.613
Private health insurance	553 (27.7)	619 (31)	0.022
Born in Australia	1728 (86.4)	1562 (78.1)	<0.01
Age group in years			<0.01
40–49	420 (21)	616 (30.8)	
50–59	684 (34.2)	573 (28.7)	
60–69	896 (44.8)	811 (40.6)	
Education			0.037
Nil	184 (9.27)	152 (7.7)	
School certificate	365 (18.4)	308 (15.6)	
High school	349 (17.6)	349 (17.7)	
Trade	161 (8.11)	178 (9)	
Certificate or diploma	323 (16.3)	362 (18.3)	
University	442 (22.3)	481 (24.4)	
Missing	160 8.06	144 7.3	
Ethnicity			<0.01
White skin	1926 (97.1)	1845 (93.5)	
Black skin	0 (0)	4 (0.2)	
Asian	2 (0.1)	24 (1.2)	
Aboriginal and Torres	2 (0.1)	4 (0.2)	
Strait Islander			
Other	2 (0.1)	7 (0.4)	
Mixed	33 (1.7)	69 (3.5)	
Missing	19 (0.97)	21 (1.1)	
Employment			0.01
Full time	770 (38.8)	842 (42.7)	
Part time	290 (14.6)	272 (13.8)	
Home	131 (6.6)	150 (7.6)	
Unemployed	28 (1.41)	31 (1.6)	
Student	14 (0.71)	10 (0.5)	
Retired	606 (30.5)	520 (26.3)	
Other	47 (2.4)	69 (3.5)	
Missing	98 4.9	80 4.1	

Case and controls matched on 5-year age categories and gender.
p-values calculated on the basis of χ^2 statistics.

Unadjusted and adjusted odds ratios (controlled for age, gender, education, employment, health insurance status, and country of birth) were derived for each diagnosis using logistic regression. While treatments can be prescribed for “off-label” indications (e.g. antihypertensive medications can be prescribed for anxiety), the estimated odds ratio will provide a defensible approximation of the true odds ratio if the probability of “off-label” prescription is equal for cases and controls.

Medical treatments were tabulated for cases and controls. Frequency and costs differences were estimated for each medical service. The results are presented in league tables, which report statistically significant ($p < 0.1$) results. Student’s t-tests were used to report differences in the mean cost of medical care for cases and controls. Wilcoxon rank-sum tests were used to test differences in median costs.

Chi-square tests were used to assess differences between those with and without KC for categorical data.

Results

Table 1 reports the demographic characteristics of sample of KC cases and controls matched by age group and sex drawn from the QSkin study. Despite matching on 5-year age groups, the cases with KC were on average 1.5 years older than the controls. Cases were also more likely to be white, born in Australia, less likely to be employed full-time, and not to have private health insurance. The average per person cost for all medical services was AUD\$2096 (median = AUD\$1230). Individuals treated for KC consumed an average cost of AUD\$2756 in medical services (median = AUD\$1762), while the controls consumed AUD\$1436 (median = AUD\$729). The difference,

AUD\$1320 ($p < 0.01$), was attributed to the additional cost of all medical treatments utilized by people with a KC.

Table 2 lists the frequencies and costs for 41 medical services, which explicitly indicated the diagnosis and/or treatment of a KC. In our sample, 4008 KC treatments were provided at a total cost of AUD\$611,778. The average cost per treatment was AUD\$153. The average cost per treated individual was AUD\$306, of which the public subsidy was AUD\$241, and the co-payment was AUD\$65. The mean number of treatments for KC was 2.0 per year. Of the individuals treated for KC, 777 (38.9%) received at least two treatments and 234 (11.7%) received at least four treatments.

By location, the most costly KC service was removal from “other body areas” followed by “face, neck or lower leg” (see Figure 1). By size of lesion, KCs < 10 mm in diameter accounted for 51% of direct treatment costs (see Figure 2).

Patients treated for KC experienced considerably greater comorbidity compared with patients not treated for KC. The KC cohort utilized an additional 366 *medical attendances*, 198 *histopathology services*, and 47 *other surgical procedures on the skin* (see Table 3). Other skin-related pathology (diagnostic skin biopsy, pre-malignant skin lesions, neoplastic skin lesions, treatment of wound by practice nurse and microscopy, and culture of the skin) and general diagnostic tests (serum chemistry, erythrocyte count, urine examination, thyroid-stimulating hormone (TSH) tests, and quantitation of a drug level) were also significantly greater among individuals treated for KC.

Table 4 reports that the KC group incurred an additional AUD\$22,296 for medical attendances, AUD\$17,908 for histopathology, and AUD\$13,202 for surgical procedures on the skin, per 100 treated patients. Premalignant skin lesions and neoplastic skin lesions cost an additional AUD\$1203 and AUD\$634 per 100 treated patients, respectively. Treatment of malignant melanoma costs an extra AUD\$371 per 100 treated patients. Diagnostic tests also figured prominently, and computed tomography (CT) scans (56507, 56807, 57341, and 56001) cost an additional AUD\$2421. Table 4 includes a number of treatments denoted by superscript d, which could be attributed to the management of KC. If all services were initiated to treat a KC or complication of KC, this would imply an additional annual cost of AUD\$21,391 per 100 KC patients or an average of AUD\$214–AUD\$306 per year as indicated in Table 2 (AUD\$30,589 per 100 patients).

Table 5 reports the percentages of cases and controls who received treatment for 17 prespecified comorbidities with unadjusted and two adjusted odds ratios. On crude (unadjusted) analysis, we found patients treated for KC were significantly more likely to also receive treatments for three cancers (melanoma, colorectal, and prostate), cardiovascular disease, hyperlipidemia, osteoporosis, rheumatoid arthritis, and tuberculosis. After controlling for socioeconomic factors correlated with KC (age, gender, education, employment, private health insurance, and born in Australia), significant associations persisted for osteoporosis, rheumatoid arthritis,

colorectal cancer, prostate cancer, and melanoma retained a positive correlation with KC. Only hypertension had an adjusted odds ratio of < 1 .

Discussion

The average costs of all medical services utilized by individuals with and without KC were AUD\$2756 and AUD\$1436, respectively. The mean difference, AUD\$1320, was equal to the cost of all additional medical treatments consumed by individuals in the KC cohort over a 12-month period. The average cost of a KC excision per patient was AUD\$306. The difference, AUD\$1014 (AUD\$1320–AUD\$306), was consumed on nonspecific medical treatments for KC (e.g. physician fees and histopathology) and correlated disease.

Individuals with KC had a lower socioeconomic status than people without a KC. They were less likely to be in full-time employment (38.8% vs 42.7%), more likely to be retired (30.5% vs 26.3%), and reported lower rates of private health insurance (27.7% vs 31.0%). The comparatively lower socioeconomic status may be a cause of much of the comorbidity we observed in this cohort. In addition to significant costs for medical attendances, other surgical procedures on the skin and histopathology, the league tables also indicate that individual treatments for cardiovascular disease and oncology contribute substantially.

Our analyses have sought to provide an overview of the costs of comorbid diseases that commonly affect patients with KC. While the correlation between melanoma and KC has been well documented,^{20,21} our analysis indicates that the costs of comorbid disease lie elsewhere. In our sample, only 2.5% of the patients treated for KC were also treated for melanoma (see Table 5), suggesting that the majority of comorbid costs were due to treatments for other conditions. After patients treated for melanoma were removed from the analysis, the average cost of comorbid disease attributable to KC was reduced from AUD\$1320 (full sample) to AUD\$1296 (AUD\$2728–AUD\$1432). The removal of osteoarthritis (AUD\$1225), rheumatoid arthritis (AUD\$1289), colorectal cancer (AUD\$1285), and prostate cancer (AUD\$1266) from the sample resulted in greater reductions in medical costs attributable to patients with KC.

While our results are broadly consistent with other published research, there are some important differences. A Danish population-based case–control study reported positive correlations between BCC and connective tissue disease, transplants, and lymphoma and between SCC and leukemia, lymphoma, and skin diseases.¹⁸ The unadjusted odds ratios indicated that KC was significantly correlated ($p < 0.1$) with rheumatoid arthritis and three cancers (colorectal, prostate, and melanoma). In addition, we found a positive association with cardiovascular disease, lipidemia, osteoporosis, and tuberculosis. Ong et al.²⁰ analyzed the International Classification of Diseases-10 (ICD-10) codes

Table 2. List of 41 medical services on the MBS for the treatment of KC: total number of procedures in KC treatment group (n = 2000) and mean cost per 100 patients.

MBS item description	Number of procedures	Cost per 100 KC patients
Removal of malignant neoplasm of skin by serial curettage or carbon dioxide laser excision–ablation: <10 lesions (30196)	799	AUD\$3711
Removal of malignant neoplasm of skin by serial curettage or carbon dioxide laser excision–ablation: >10 lesions (30197)	15	AUD\$467.56
Removal of malignant neoplasm of skin by cryotherapy: <10 lesions (30202)	230	AUD\$425.43
Removal of malignant neoplasm of skin by cryotherapy: >10 lesions (30203)	28	AUD\$202.58
Removal of malignant neoplasm of skin and cartilage by cryotherapy: >10 lesions (30205)	0	AUD\$0.00
Mircographically controlled serial excision of skin tumor with histological examination: <6 lesions (31000)	19	AUD\$800.26
Mircographically controlled serial excision of skin tumor with histological examination: 7–12 lesions (31001)	8	AUD\$464
Mircographically controlled serial excision of skin tumor with histological examination: >13 lesions (31002)	1	AUD\$55
<i>Removal from nose, eyelid, lip, ear, digit, or genitalia by surgical excision</i>		
Removal of BCC or SCC with malignancy confirmed: <10 mm diameter (31255)	318	AUD\$2992
Removal of residual BCC or SCC by original GP, specimen sent to histology: original tumor < 10 mm diameter (31256)	14	AUD\$116
Removal of residual BCC or SCC by nonoriginal GP, specimen sent to histology: original tumor < 10 mm diameter (31257)	4	AUD\$49
Removal of recurrent BCC or SCC, malignancy confirmed by histology: original tumor < 10 mm diameter (31258)	2	AUD\$14
Removal of BCC or SCC with malignancy confirmed: >10 mm diameter (31260)	84	AUD\$972
Removal of residual BCC or SCC by original GP, specimen sent to histology: original tumor > 10 mm diameter (31261)	5	AUD\$82
Removal of residual BCC or SCC by nonoriginal GP, specimen sent to histology: original tumor > 10 mm diameter (31262)	1	AUD\$21
Removal of recurrent BCC or SCC, malignancy confirmed by histology: original tumor > 10 mm diameter (31263)	0	AUD\$0
<i>Removal from face, neck (anterior to the sternomastoid muscles), or lower leg (mid-calf to ankle) by surgical excision</i>		
Removal of BCC or SCC, malignancy confirmed by histology: <10 mm diameter (31265)	595	AUD\$4765
Removal of residual BCC or SCC, by original GP, specimen sent to histology: original tumor < 10 mm diameter (31266)	14	AUD\$115
Removal of residual BCC or SCC, by nonoriginal GP, specimen sent to histology: original tumor < 10 mm diameter (31267)	3	AUD\$21
Removal of recurrent BCC or SCC, malignancy confirmed by histology: original tumor > 10 mm diameter (31268)	2	AUD\$15
Removal of BCC or SCC with malignancy confirmed: 10–20 mm diameter (31270)	229	AUD\$2549
Removal of residual BCC or SCC by original GP, specimen sent to histology: original tumor 10–20 mm diameter (31271)	3	AUD\$33
Removal of residual BCC or SCC by nonoriginal GP, specimen sent to histology: original tumor 10–20 mm diameter (31272)	0	AUD\$0
Removal of recurrent, BCC or SCC, malignancy confirmed: original tumor 10–20 mm diameter (31273)	2	AUD\$21
Removal of BCC or SCC, malignancy confirmed: >20 mm diameter (31275)	54	AUD\$653
Removal of residual BCC or SCC, by original GP, specimen sent to histology: original tumor > 20 mm diameter (31276)	1	AUD\$6
Removal of residual BCC or SCC, by nonoriginal GP: original tumor > 20 mm diameter (31277)	1	AUD\$5
Removal of recurrent BCC or SCC, malignancy confirmed: original tumor > 20 mm diameter (31278)	0	AUD\$0
<i>Removal from other body areas by surgical excision</i>		
Removal of BCC or SCC, malignancy confirmed by histology: <10 mm diameter (31280)	1049	AUD\$7258
Removal of residual BCC or SCC, by original GP, specimen sent to histology: original tumor < 10 mm diameter (31281)	15	AUD\$100

(Continued)

Table 2. (Continued)

MBS item description	Number of procedures	Cost per 100 KC patients
Removal of residual BCC or SCC, by nonoriginal GP, specimen sent to histology: original tumor < 10 mm diameter (31282)	1	AUD\$8
Removal of recurrent BCC or SCC, malignancy confirmed by histology: original tumor > 10 mm diameter (31283)	0	AUD\$0
Removal of BCC or SCC with malignancy confirmed: 10–20 mm diameter (31285)	435	AUD\$3891
Removal of residual BCC or SCC by original GP, specimen sent to histology: original tumor 10–20 mm diameter (31286)	4	AUD\$31
Removal of residual BCC or SCC by nonoriginal GP, specimen sent to histology: original tumor 10–20 mm diameter (31287)	1	AUD\$9
Removal of recurrent, BCC or SCC, malignancy confirmed: original tumor 10–20 mm diameter (31288)	0	AUD\$0
Removal of BCC or SCC, malignancy confirmed: >20 mm diameter (31290)	58	AUD\$547
Removal of residual BCC or SCC, by original GP, specimen sent to histology: original tumor > 20 mm diameter (31291)	0	AUD\$0
Removal of residual BCC or SCC, by nonoriginal GP: original tumor > 20 mm diameter (31292)	3	AUD\$52
Removal of recurrent BCC or SCC, malignancy confirmed: original tumor > 20 mm diameter (31293)	2	AUD\$18
Removal of recurrent BCC or SCC, by nonoriginal GP, malignancy confirmed: tumor size unspecified (31295)	8	AUD\$120
Total	4008	AUD\$30,589

MBS: Medicare Benefits Scheme; KC: keratinocyte cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; GP: general practitioner.




Figure 1. Keratinocyte cancer: proportion of costs by location of lesion.

(1) Removal from other body area (MBS items 31280, 31281, 31282, 31283, 31285, 31286, 31287, 31288, 31290, 31291, 31292, 31293, and 31295); (2) removal from nose eyelid, lip ear, digit, or genitalia (MBS items 31255, 31256, 31257, 31258, 31260, 31261, 31262, and 31263); (3) removal from face, neck, or lower leg (MBS items 31265, 31266, 31267, 31268, 31270, 31271, 31272, 31273, 31275, 31276, 31277, and 31278); and (4) unspecified area (30196, 30197, 30202, 30203, 30205, 31000, 31001, and 31002).




Figure 2. Keratinocyte cancer: proportion of costs by size of lesion treated.

(1) KC < 10 mm (MBS items 31255, 31256, 31257, 31258, 31265, 31266, 31267, 31268, 31280, 31281, 31282, and 31283); (2) KC > 20 mm (MBS items 31275, 31277, 31290, 31276, 31278, 31291, 31292, and 31293); (3) KC 10–20 mm (MBS items 31270, 31285, 31287, 31271, 31272, 31273, 31286, and 31288); (4) KC > 10 mm removed from nose, eyelid, lip, ear, digit, or genitalia (MBS items 31260, 31261, 31262, and 31263); and (5) unspecified size (MBS items 30196, 30197, 30202, 30203, 30205, 31000, 31001, 31002, and 31295).

in 8 million hospitalized patients in the United Kingdom in patients aged 45–69 years treated for KC. They reported statistically significant relative risks for melanoma (9.4), breast cancer (1.25), prostate cancer (1.21), colon cancer (1.30), and rectal cancer (2.59). The corresponding unadjusted odds ratios from our analysis were 6.38 (melanoma), 1.53 (prostate cancer), and 1.32 (colorectal cancer); however, the

unadjusted odds ratio for breast cancer (1.1) did not reach statistical significance.

The adjusted odds ratios for cardiovascular disease, lipi-demia, and tuberculosis were not statistically significant. The adjusted odds ratios for the three cancers (colorectal, prostate, and melanoma), osteoporosis, and rheumatoid arthritis remained >1. Notably, the adjusted odds ratio for

Table 3. Twenty medical services with the greatest difference in rates between the KC and non-KC patient groups (rates of service per 100 patients).

MBS description	With KC	Without KC	Difference	Wilcoxon rank-sum
Medical attendances ^a	1079	713	366	<0.01
Histopathology ^b	223	25	198	<0.01
Surgical procedures on the skin ^c	55	8	47	<0.01
Diagnostic biopsy of skin or mucous membrane (30071)	104	10	94	<0.01
Premalignant skin lesions (30192)	46	9	37	<0.01
General serum chemistry 5 or more tests (66512)	138	101	37	<0.01
Erythrocyte count, hematocrit (65070)	104	73	31	<0.01
Treatment of wound by practice nurse (10996)	21	3	18	<0.01
Pre-anesthesia brief consultation (17610)	34	17	17	<0.01
Neoplastic skin lesions (30195)	16	3	13	<0.01
Psoralen and ultraviolet A or B therapy (14050)	9	0	9	0.01
Electrocardiogram (11700)	24	15	9	<0.01
Urine examination (69333)	27	20	7	<0.01
Trigeminal nerve injection (18236)	5	0	5	<0.01
Review a GP management plan (732)	15	10	5	<0.01
Thyroid-stimulating hormone test (66716)	35	31	4	0.04
Quantitation of a drug level (66812)	4	1	4	0.01
Micro or cult skin (69306)	6	2	4	0.01
Foot, ankle, leg, knee, or femur (57521)	16	12	3	0.02
Subsequent optometric consultation (10918)	19	16	3	0.07

MBS: Medicare Benefits Scheme; KC: keratinocyte cancer; GP: general practitioner.

Service definitions by MBS item numbers.

^aMedical attendances: 3, 23, 36, 44, 193, 197, 199, 2501, 2503, 2504, 2517, 2521, 2525, 2546, 2552, 5000, 5020, 5040, 5060, 86014, 104, 105, 110, and 116.

^bHistology: 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836, and 72838.

^cOther surgical procedures on skin: single-stage local flap: 45200, 45203, 45206, 45000, and 45003; free grafting: 45400, 45403, 45439, 45442, 45445, 45448, and 45451; lip, eyelid, or ear, full thickness wedge: 45665; H-flap or double advancement flap: 45207; vermilionectomy: 45668 and 45669; whole thickness reconstruction of eyelid: 45614; tumor, cyst, ulcer, or scar removal: 31200, 31205, 31210, 31215, 31220, 31225, 31230, 31235, 31240, and 52045; lens replacement: 42702.

hypertension was <1. This suggests that, perhaps, the association between KC and cardiovascular disease and lipidemia may be due to behavioral characteristics associated with socioeconomic status, for example, poor understanding of risk factors, whereas the association between KC and other cancers may instead be due to underlying biological factors. The adjusted odds ratio for antihypertensive medications (0.76) was unexpected and not easily explained.

Although we considered the possibility that KC might offer some “protective effect” against diseases mediated by ultraviolet (UV) light (e.g. second solid primary cancers²⁷ and prostate cancer²⁵), we found no evidence of a negative correlation between KC and treatments for these diseases. Research has confirmed that Australians increase their exposure to UV radiation due a concern about vitamin D deficiency.⁴⁸ While the importance of vitamin D for bone health should not be ignored, these results suggest that public concern for vitamin D deficiency should not be allowed to undermine public health campaigns to minimize exposure to UV radiation.

The principal strength of our study was our capacity to access cost data obtained for a large population-based sample.

These survey data were linked to medical and pharmaceutical item codes, which enabled the medical costs of individual treated for a KC to be analyzed. First, we were able to report on the cost of 41 medical services explicitly attributable to the management of KC. Second, coding algorithms were used to identify treatments for 17 other diseases, identified by the literature as potentially correlated with KC. While our list was not intended to be all-encompassing, we believe that it does include most of the likely possibilities. The 17 comorbidities that we identified include 8 of the 20 most frequently managed problems by Australia’s GPs.⁴³

Our definition of KC did not include the growing number topical agents now available to treat KC. Because most topical agents used for KC treatment do not incur a Medicare rebate, we could not identify such instances in our cohort. This would only bias our estimates if patients used only topical agents to treat their cancers. In our sample, we could identify only 25 individuals who were prescribed imiquimod (PBS item numbers: 02546B, 04134N, and 04559Y), a topical treatment for KC. A cross tabulation indicated that 21 of these individuals had received other KC treatments, and only 4 were coded as having received no other KC treatment.

Table 4. Twenty medical services with the greatest difference in costs between the KC and non-KC patient groups (costs per 100 patients).

Service description (MBS no.)	Average cost per service (in 2012 AUD\$)	With KC	Without KC	Difference	Wilcoxon rank-sum p-value
Medical attendances ^a	AUD\$79	AUD\$63,407	AUD\$41,111	AUD\$22,296	<0.01
Histopathology ^b	AUD\$104	AUD\$20,642	AUD\$2734	AUD\$17,908	<0.01
Surgical procedures on the skin ^{c,d}	AUD\$259	AUD\$14,081	AUD\$879	AUD\$13,202	<0.01
Diagnostic biopsy of skin (30071) ^d	AUD\$42	AUD\$4311	AUD\$401	AUD\$3911	<0.01
Anesthesia for procedures on the skin (20100) ^d	AUD\$350	AUD\$1678	AUD\$17	AUD\$1660	<0.01
Pre-anesthesia brief consultation (17610)	AUD\$73	AUD\$2522	AUD\$1278	AUD\$1244	<0.01
Premalignant skin lesions (30192) ^d	AUD\$33	AUD\$1489	AUD\$286	AUD\$1203	<0.01
CT scan of chest, abdomen, and pelvis (56507)	AUD\$474	AUD\$2134	AUD\$1138	AUD\$996	<0.01
Assistance at operation (51303)	AUD\$373	AUD\$1901	AUD\$1062	AUD\$839	<0.01
Anesthesia for procedures on nose (20100) ^d	AUD\$459	AUD\$896	AUD\$115	AUD\$781	<0.01
CT scan of upper abdomen and pelvis (56807)	AUD\$560	AUD\$1904	AUD\$1176	AUD\$728	0.06
Knee arthroscopy (49561)	AUD\$1323	AUD\$1323	AUD\$595	AUD\$728	0.06
Neoplastic skin lesions (30195) ^d	AUD\$50	AUD\$777	AUD\$143	AUD\$634	<0.01
Dosimetry (15562)	AUD\$1225	AUD\$796	AUD\$184	AUD\$613	0.03
General serum chemistry 5 or more tests (66512)	AUD\$17	AUD\$2299	AUD\$1688	AUD\$611	<0.01
Psoralen and ultraviolet A or B therapy (14050)	AUD\$44	AUD\$387	AUD\$0	AUD\$387	0.01
Malignant melanoma < 10 mm (31325)	AUD\$247	AUD\$396	AUD\$25	AUD\$371	<0.01
CT with surgery (57341)	AUD\$447	AUD\$536	AUD\$179	AUD\$358	0.01
Review a GP management plan (732)	AUD\$70	AUD\$1025	AUD\$676	AUD\$349	<0.01
CT of brain without contrast (56001)	AUD\$206	AUD\$587	AUD\$247	AUD\$340	<0.01

MBS: Medicare Benefits Scheme; KC: keratinocyte cancer; GP: general practitioner; CT: computed tomography.

Service definitions by MBS item numbers.

^aMedical attendances (see Table 3).

^bHistopathology (see Table 3).

^cOther surgical procedures on skin (see Table 3).

^dProcedures potentially indicated to treat KC or consequence of KC.

Table 5. Seventeen comorbid diseases for individuals treated for KC.

Comorbidities	Patients with KC n (%)	Patients without KC n (%)	Unadjusted odds ratio (p-value)	Adjusted odds ratio* (p-value)
Cardiovascular disease	778 (38.9)	707 (35.35)	1.16 (0.02)	0.98 (0.81)
Lipidemia ^a	657 (32.85)	407 (20.35)	1.16 (0.03)	1.01 (0.91)
Hypertension ^a	359 (17.95)	364 (18.2)	0.98 (0.84)	0.76 (<0.01)
Depression ^a	311 (15.55)	302 (15.1)	1.04 (0.69)	1.01 (0.91)
Osteoporosis	364 (18.2)	303 (15.15)	1.25 (0.01)	1.16 (0.1)
Rheumatoid arthritis ^a	306 (15.3)	239 (11.95)	1.33 (<0.01)	1.21 (0.06)
Asthma ^a	257 (12.85)	261 (13.05)	1.02 (0.85)	0.92 (0.41)
Diabetes ^a	202 (10.1)	179 (8.95)	1.14 (0.22)	1.04 (0.75)
Colorectal cancer	188 (9.4)	146 (7.3)	1.32 (0.02)	1.26 (0.05)
Prostate cancer	195 (9.75)	132 (6.6)	1.53 (<0.01)	1.38 (0.01)
Breast cancer	100 (5)	91 (4.55)	1.1 (0.51)	1.08 (0.63)
Anxiety	60 (3)	67 (3.35)	0.89 (0.53)	0.83 (0.33)
Melanoma	50 (2.5)	8 (0.4)	6.38 (<0.01)	6.15 (<0.01)
Bronchitis ^a	45 (2.25)	40 (2)	1.13 (0.58)	1 (0.99)
Tuberculosis	31 (1.55)	19 (0.95)	1.64 (0.09)	1.58 (0.13)
Parkinson's disease	14 (0.7)	8 (0.4)	1.76 (0.21)	1.55 (0.34)
Multiple sclerosis	3 (0.15)	5 (0.25)	0.6 (0.48)	0.55 (0.41)

KC: keratinocyte cancer; GP: general practitioner.

The cases and controls were matched on gender and 5-year age groups.

^aSeven of the 10 most frequently managed problems by Australia's GPs. The three nonincluded categories were *Checkup all, immunization or vaccination, and prescription*.

*Odds ratios adjusted for age, gender, education, employment, private health insurance, and born in Australia.

Hence, the 41 selected MBS codes provide a workable definition of a KC treatment. While administrative data are potentially prone to misclassification errors, particularly for inferring diagnoses, it has been recently shown in these data that Medicare records for skin cancer treatments have very high validity when compared against histopathology reports.⁴⁹ Therefore, we believe that misclassification of skin cancer history is very unlikely to have biased our estimates of treatment costs to any substantial extent.

The principal limitation of our analysis was an inability to differentiate between generic medical treatments used to manage KC and the treatment of any correlated diseases. Itemized costs directly related to treatment can only account for 23.2% of the additional AUD\$1320 of medical services used. Ideally, interrogation of the medical record would enable these AUD\$1014 of residual costs to be differentiated. However, with a large dataset, this method may be prohibitively costly, and where patients present with multiple complaints, some allocation overheads (e.g. attendance fees) would be required. Any future analysis, which could differentiate between these two classes of medical costs, would be beneficial, as it would help policy-makers to tailor preventive health-care messages and target the delivery of medical resource to this cohort.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for the study was received from the QIMR Berghofer Medical Research Institute Human Research Ethics Committee (P1309), the Department of Health and the Queensland University of Technology.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Rowell received funding through a postdoctoral fellowship from the National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Sun and Health. Prof. Whiteman is supported by a Research Fellowship from the NHMRC. The QSkin study is supported by a Program Grant from the NHMRC (552429).

Informed consent

Written informed consent was obtained from all subjects before the study.

References

1. Albert MR and Weinstock MA. Keratinocyte carcinoma. *CA Cancer J Clin* 2003; 53: 292–302.
2. Chen JG, Fleischer AB, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. *Dermatol Surg* 2001; 27: 1035–1038.
3. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. *J Am Acad Dermatol* 2003; 48: 425–429.
4. Krueger H. The economic burden of skin cancer in Canada: current and projected. *Final report, Canadian Partnership against Cancer, Toronto, ON, Canada*, 26 February 2010.
5. Rogers HW and Coldiron BM. Analysis of skin cancer treatment and costs in the United States Medicare population, 1996–2008. *Dermatol Surg* 2013; 39: 35–42.
6. Nilsson GH, Carlsson L, Dal H, et al. Skin diseases caused by ultraviolet radiation: the cost of illness. *Int J Technol Assess Health Care* 2003; 19: 724–730.
7. Tinghog G, Carlsson P, Synnerstad I, et al. Societal cost of skin cancer in Sweden in 2005. *Acta Derm Venereol* 2008; 88: 467–473.
8. Stang A, Stausberg J, Boedeker W, et al. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. *J Eur Acad Dermatol Venereol* 2008; 22: 65–72.
9. Bentzen J, Kjellberg J, Thorgaard C, et al. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. *Eur J Cancer Prev* 2013; 22: 569–576.
10. Fransen M, Karahalios A, Sharma N, et al. Non-melanoma skin cancer in Australia. *Med J Aust* 2012; 197: 565–568.
11. O’Dea D. *The costs of skin cancer to New Zealand*. Wellington, New Zealand: The Cancer Society of New Zealand, 2009.
12. Souza RJ, Mattedi AP, Correa MP, et al. An estimate of the cost of treating non-melanoma skin cancer in the state of Sao Paulo, Brazil. *An Bras Dermatol* 2011; 86: 657–662.
13. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States. *Arch Dermatol* 2006; 2010(146): 283.
14. Hayes RC, Leonfellner S, Pilgrim W, et al. Incidence of non-melanoma skin cancer in New Brunswick, Canada, 1992 to 2001. *J Cutan Med Surg* 2006; 11: 45–52.
15. Levi F, Te V, Randimbison L, et al. Trends in skin cancer incidence in Vaud: an update, 1976–1998. *Eur J Cancer Prev* 2001; 10: 371–373.
16. Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. *J Natl Cancer Inst* 2008; 100: 1215–1222.
17. Frisch M and Melbye M. New primary cancers after squamous cell skin cancer. *Am J Epidemiol* 1995; 141: 916–922.
18. Jensen AØ, Olesen AB, Dethlefsen C, et al. Chronic diseases requiring hospitalization and risk of non-melanoma skin cancers—a population based study from Denmark. *J Invest Dermatol* 2007; 128: 926–931.
19. Jensen AØ, Lamberg AL and Olesen AB. Epidemiology of non-melanoma skin cancer. In: Jemec GB, Kemény L and Miech D (eds) *Non-surgical treatment of keratinocyte skin cancer*. Heidelberg: Springer, 2010; pp.15–24.
20. Ong ELH, Goldacre R, Hoang U, et al. Subsequent primary malignancies in patients with nonmelanoma skin cancer in England: a National Record-Linkage Study. *Cancer Epidemiol Biomarkers Prev* 2014; 23: 490–498.
21. Cantwell M, Murray L, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. *Br J Cancer* 2009; 100: 174–177.
22. Wassberg C, Thörn M, Yuen J, et al. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. *Int J Cancer* 1999; 80: 511–515.

23. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology* 2012; 143: 390.e1–399.e1.
24. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. *Am J Prev Med* 2007; 32: 210–216.
25. De Vries E, Soerjomataram I, Houterman S, et al. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? *Am J Epidemiol* 2007; 165: 966–972.
26. Grant WB, Garland CF and Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. *Photochem Photobiol* 2005; 81: 1276–1286.
27. Tuohimaa P, Pukkala E, Scélo G, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. *Eur J Cancer* 2007; 43: 1701–1712.
28. Olsen CM, Green AC, Neale RE, et al. Cohort profile: The QSkin Sun and Health Study. *Int J Epidemiol* 2012; 41: 929–929-i.
29. Morze CJ, Olsen CM, Perry SL, et al. Good test–retest reproducibility for an instrument to capture self-reported melanoma risk factors. *J Clin Epidemiol* 2012; 65: 1329–1336.
30. Souberbielle J-C, Body J-J, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. *Autoimmun Rev* 2010; 9: 709–715.
31. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. *Arthritis Rheum* 2004; 50: 72–77.
32. Van der Mei I. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. *J Neurol* 2007; 254: 581–590.
33. Milaneschi Y, Shardell M, Corsi AM, et al. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. *J Clin Endocrinol Metab* 2010; 95: 3225–3233.
34. Armstrong D, Meenagh G, Bickle I, et al. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. *Clin Rheumatol* 2007; 26: 551–554.
35. Scragg R, Holdaway I, Jackson R, et al. Plasma 25-hydroxyvitamin D and its relation to physical activity and other heart disease risk factors in the general population. *Ann Epidemiol* 1992; 2: 697–703.
36. Chuang TY, Lewis D and Spandau D. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: a pilot study. *Br J Dermatol* 2005; 153: 552–557.
37. Jhappan C, Noonan FP and Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. *Oncogene* 2003; 22: 3099–3112.
38. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer* 2010; 128: 1414–1424.
39. Avenell A, Gillespie W, Gillespie L, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *ACP J Club* 2006; 144: 14.
40. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007; 357: 266–281.
41. Knekt P, Kilkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. *Arch Neurol* 2010; 67: 808–811.
42. Nnoaham KE and Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. *Int J Epidemiol* 2008; 37: 113–119.
43. Britt H, Miller GC, Charles J, et al. *General practice activity in Australia 2010–11*. General practice series no. 29, November 2011. Sydney, NSW, Australia: Sydney University Press.
44. Porter R and Kaplan J. *The Merck manual online*. <http://www.merck.com/mmpe/index.html> (accessed 1 June 2013).
45. Australian Government Department of Health, MBS Online Medical Benefits Schedule. <http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1> (accessed 1 June 2013).
46. Australian Government Department of Health, The Pharmaceutical Benefits Scheme. <http://www.pbs.gov.au/pbs/home> (accessed 1 June 2013).
47. Rowell D, Gordon LG, Olsen CM, et al. A reconstruction of a medical history from administrative data: with an application to the cost of skin cancer. *Health Econ Rev* 2015; 5: 1–11.
48. Dobbins SJ and Volkov A. *2010–11 National Sun Protection Survey: report 2. Australians’ sun protective behaviours and sunburn incidence on summer weekends, 2010–11 and comparison with 2003–04 and 2006–07* (unpublished). Melbourne, VIC, Australia: Centre for Behavioural Research in Cancer, Cancer Council Victoria, 2010.
49. Thompson BS, Olsen CM, Subramaniam P, et al. Medicare claims data reliably identify treatments for basal cell carcinoma and squamous cell carcinoma: a prospective cohort study. *Aust N Z J Public Health*. Epub ahead of print 11 November 2015. DOI: 10.1111/1753-6405.12478.